CareMax, Inc.
CareMax, Inc. (CMAX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cmax · stock forecast · 5 analysts (3M) · FMP · updated Nov 6, 2025
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Hold
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$3.00
Consensus
$2.60
+516.8% upside
Low
$2.20
Median: $2.6 · Last Close: $0.42
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$2.60
516.8% upside
High Target
$3
611.7%
Low Target
$2.2
421.9%
Current Price
$0.42
as of today
Based on analyst price targets, the CMAX stock price prediction for the next 12 months ranges from $2.2 to $3. The consensus CMAX price forecast of $2.60 implies 516.8% upside from the current price of $0.42.
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.42 | ↑ 0.00% |
1-day model range: $0.42–$0.42. Peak: $0.42 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · CMAX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-04-01 | UBS | Maintains | Neutral→Neutral |
| 2023-11-17 | UBS | Downgrade ↓ | Buy→Neutral |
| 2023-11-10 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-01-05 | UBS | Maintains | Buy→Buy |
| 2022-09-07 | Truist Securities | Maintains | Hold→Hold |
| 2021-10-20 | Jefferies | Maintains | Buy→Buy |
| 2021-09-12 | Piper Sandler | Upgrade ↑ | Neutral→Overweight |
| 2021-09-10 | Cowen & Co. | Maintains | Outperform→Outperform |
| 2021-07-01 | Piper Sandler | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on CareMax, Inc. (CMAX) stock. Of the recent 9 rating actions, 1 were upgrades and 2 were downgrades. 5 analysts currently cover CMAX.
Analyst Recommendation Trends
CMAX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$786M
↓ 43.1% YoY
Revenue Next Year
$933M
↑ 18.6% YoY
EPS This Year
$-49.50
EPS Next Year
$-24.41
↓ 50.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast CMAX EPS of $-49.50 for the current fiscal year, based on estimates from 1 analysts. The CMAX revenue forecast is $786M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CMAX stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CMAX price target is $2.60 (+516.8% upside), with an analyst consensus of Hold.
The CMAX short-term stock prediction for tomorrow is $0.42 (+0.00%).
CareMax, Inc. trades on NASDAQ under the ticker CMAX. The CMAX stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 40% of covering analysts.
Frequently asked questions
CMAX forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month CMAX price target is $2.60, with a high forecast of $3.00 and a low of $2.20. The median price target is shown in the chart above when available. This implies +516.8% potential upside from the current price of $0.42.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.